HUE052008T2 - Trimert stabilizáló HIV-burokfehérje-mutációk - Google Patents

Trimert stabilizáló HIV-burokfehérje-mutációk

Info

Publication number: HUE052008T2
Authority: HU; Hungary
Prior art keywords: envelope protein; hiv envelope; protein mutations; trimer stabilizing; stabilizing hiv
Prior art date: 2016-09-15

Application number

HUE17769027A

Other languages

English (en)

Inventor

Lucy Rutten

Daphne Truan

Nika Strokappe

Johannes Langedijk

Original Assignee

Janssen Vaccines & Prevention Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-09-15

Filing date

2017-09-14

Publication date

2021-04-28

2017-09-14 Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv

2021-04-28 Publication of HUE052008T2 publication Critical patent/HUE052008T2/hu

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

HUE17769027A 2016-09-15 2017-09-14 Trimert stabilizáló HIV-burokfehérje-mutációk HUE052008T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP16188866		2016-09-15

Publications (1)

Publication Number	Publication Date
HUE052008T2 true HUE052008T2 (hu)	2021-04-28

Family

ID=57017955

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE17769027A HUE052008T2 (hu)	2016-09-15	2017-09-14	Trimert stabilizáló HIV-burokfehérje-mutációk

Country Status (30)

Country	Link
US (3)	US10793607B2 (hu)
EP (2)	EP3512543B1 (hu)
JP (2)	JP7178344B2 (hu)
KR (1)	KR102513146B1 (hu)
CN (1)	CN109689091A (hu)
AR (1)	AR109528A1 (hu)
AU (2)	AU2017327672B2 (hu)
BR (1)	BR112019004593A2 (hu)
CA (1)	CA3036959A1 (hu)
CY (1)	CY1124518T1 (hu)
DK (1)	DK3512543T3 (hu)
EA (1)	EA201990715A1 (hu)
ES (1)	ES2824525T3 (hu)
HR (1)	HRP20201458T1 (hu)
HU (1)	HUE052008T2 (hu)
IL (2)	IL265186B (hu)
LT (1)	LT3512543T (hu)
MA (1)	MA46230B1 (hu)
MD (1)	MD3512543T2 (hu)
MX (1)	MX2019002938A (hu)
MY (1)	MY190534A (hu)
PH (1)	PH12019500280A1 (hu)
PL (1)	PL3512543T3 (hu)
PT (1)	PT3512543T (hu)
RS (1)	RS60919B1 (hu)
SG (2)	SG10202001956UA (hu)
SI (1)	SI3512543T1 (hu)
TW (1)	TWI742158B (hu)
WO (1)	WO2018050747A1 (hu)
ZA (1)	ZA201901597B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3390430B1 (en)	2015-12-15	2019-08-28	Janssen Vaccines & Prevention B.V.	Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
US11246920B2 (en)	2016-03-03	2022-02-15	Duke University	Compositions and methods for inducing HIV-1 antibodies
US11318197B2 (en)	2016-03-03	2022-05-03	Duke University	Compositions and methods for inducing HIV-1 antibodies
WO2017192434A1 (en) *	2016-05-02	2017-11-09	The Scripps Research Institute	Compositions and methods related to hiv-1 immunogens
CN109219448B (zh)	2016-06-16	2022-09-20	扬森疫苗与预防公司	Hiv疫苗配制品
US10307477B2 (en)	2016-09-02	2019-06-04	Janssen Vaccines & Prevention B.V.	Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US10793607B2 (en) *	2016-09-15	2020-10-06	Janssen Vaccines & Prevention B.V.	Trimer stabilizing HIV envelope protein mutations
US11161895B2 (en)	2016-10-03	2021-11-02	Duke University	Methods to identify immunogens by targeting improbable mutations
KR20200015759A (ko)	2017-06-15	2020-02-12	얀센 백신스 앤드 프리벤션 비.브이.	Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법
AU2018304502B2 (en)	2017-07-19	2022-03-31	Janssen Vaccines & Prevention B.V.	Trimer stabilizing HIV envelope protein mutations
SG11202012313PA (en)	2018-06-13	2021-01-28	Scripps Research Inst	Nanoparticle vaccines with novel structural components
EA038287B1 (ru) *	2018-06-18	2021-08-04	Янссен Вэксинс Энд Превеншн Б.В.	Стабилизирующие тример мутации белка оболочки hiv
CA3114870A1 (en) *	2018-10-01	2020-04-09	Duke University	Hiv-1 envelope stabilizing mutations
JP2022523044A (ja) *	2019-01-22	2022-04-21	ブルーバードバイオ，インコーポレイテッド	ウイルスベクターを製造するための方法及びシステム
CN110184298B (zh) *	2019-05-15	2023-05-16	武汉璟泓科技股份有限公司	Hiv突变型表面糖蛋白及其纳米化抗原与制备方法
WO2021097254A1 (en) *	2019-11-14	2021-05-20	Emory University	Hiv immunogens, vaccines, and methods related thereto
US20240000919A1 (en) *	2020-11-12	2024-01-04	Xiamen University	Modified envelope protein of human immunodeficiency virus and use thereof
WO2022180007A1 (en)	2021-02-23	2022-09-01	Janssen Vaccines & Prevention B.V.	Trimer stabilizing hiv envelope protein mutation
WO2023156505A1 (en)	2022-02-17	2023-08-24	Janssen Vaccines & Prevention B.V.	Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l
WO2023192835A1 (en) *	2022-03-27	2023-10-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Base-covered hiv-1 envelope ectodomains and their use

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4603112A (en)	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
CA1341245C (en)	1988-01-12	2001-06-05	F. Hoffmann-La Roche Ag	Recombinant vaccinia virus mva
US5298416A (en)	1989-01-18	1994-03-29	British Technology Group Ltd.	Attenuated polioviruses
US5505947A (en)	1994-05-27	1996-04-09	The University Of North Carolina At Chapel Hill	Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en)	1995-07-04	2004-08-16	Gsf Forschungszentrum Fur Unwe	A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en)	1995-12-07	2002-11-12	Diversa Corporation	Non-stochastic generation of genetic vaccines
US5761893A (en)	1996-10-22	1998-06-09	Lofquist Welding, Inc.	Crop saving attachment for the snouts of combines
US7468181B2 (en)	2002-04-25	2008-12-23	Crucell Holland B.V.	Means and methods for the production of adenovirus vectors
US6710173B1 (en)	1999-06-25	2004-03-23	Progenics Pharmaceuticals, Inc.	Stabilized viral envelope proteins and uses thereof
CA2384271A1 (en)	1999-09-17	2001-03-22	Joseph G. Sodroski	Stabilized soluble glycoprotein trimers
IL154712A0 (en)	2000-11-23	2003-10-31	Bavarian Nordic As	Modified vaccinia ankara virus variant
EP2345665A3 (en)	2001-12-04	2012-02-15	Bavarian Nordic A/S	Flavivirus NS1 subunit vaccine
WO2004044155A2 (en)	2002-11-07	2004-05-27	Beth Israel Deaconess Medical Center	MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
US7901690B2 (en)	2002-12-03	2011-03-08	University Of Massachusetts	Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
WO2004087201A2 (en)	2003-03-28	2004-10-14	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Mva virus expressing modified hiv envelope, gag, and pol genes
US20070166784A1 (en)	2003-09-15	2007-07-19	Barnett Susan W	Combination approaches for generating immune responses
EP2371387A3 (en) *	2003-09-17	2012-01-25	Duke University	HIV consensus sequence antigens and their use in vaccina
WO2005052119A2 (en)	2003-11-19	2005-06-09	Beth Israel Deaconess Medical Center	Adjuvants of immune response
US20080274134A1 (en)	2004-06-15	2008-11-06	Norbert Schulke	Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex
CA2573702C (en)	2004-07-16	2013-10-15	The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services	Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv
AU2005293568B2 (en)	2004-10-13	2010-10-28	Beth Israel Deaconess Medical Center Inc.	Improved adenoviral vectors and uses thereof
CN1857345B (zh) *	2005-05-08	2010-09-01	谢秀琼	一种治疗偏头痛的药物组合物及其制备方法
WO2007005934A2 (en)	2005-07-06	2007-01-11	University Of Maryland Biotechnology Institute	Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
CN101969996A (zh)	2005-08-23	2011-02-09	加利福尼亚大学董事会	多价疫苗
WO2007104792A2 (en)	2006-03-16	2007-09-20	Crucell Holland B.V.	Recombinant adenoviruses based on serotype 26 and 48, and use thereof
CA2655934A1 (en)	2006-06-19	2007-12-27	Progenics Pharmaceuticals, Inc.	Soluble stabilized trimeric hiv env proteins and uses thereof
CA2667358A1 (en)	2006-10-23	2008-05-29	Progenics Pharmaceuticals, Inc.	Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
US20080279879A1 (en)	2006-11-17	2008-11-13	New York University	INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
MX362698B (es)	2007-03-02	2019-02-01	Glaxosmithkline Biologicals Sa	Metodo novedoso y composiciones.
SI2340038T1 (en)	2008-10-10	2018-05-31	Children's Medical Center Corporation	A biochemically stabilized HIV-1 ENV TRIMER vaccine
DK2358757T3 (da)	2008-11-18	2019-01-02	Beth Israel Deaconess Medical Ct Inc	Antivirale vacciner med forbedret cellulær immunogenicitet
WO2010096561A1 (en)	2009-02-18	2010-08-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Synthetic hiv/siv gag proteins and uses thereof
US9241986B2 (en)	2010-01-04	2016-01-26	Kj Biosciences Llc	DPS fusion proteins for use in vaccines and diagnostics
EP2529010B1 (en)	2010-01-28	2017-04-19	Bavarian Nordic A/S	Vaccinia virus mutants containing the major genomic deletions of mva
PT3556396T (pt)	2010-08-31	2022-07-04	Scripps Research Inst	Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
WO2013036791A2 (en)	2011-09-09	2013-03-14	Beth Israel Deaconess Medical Center, Inc.	Modified adenoviral vectors and methods of treatment using same
US20130189754A1 (en)	2011-09-12	2013-07-25	International Aids Vaccine Initiative	Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2766037A4 (en)	2011-10-12	2015-08-05	Scripps Research Inst	HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF
WO2014047261A1 (en)	2012-09-19	2014-03-27	Beth Israel Deaconess Medical Center, Inc.	Viruses associated with immunodeficiency and enteropathy and methods using same
JP2015536147A (ja)	2012-11-16	2015-12-21	ベスイスラエルデアコネスメディカルセンターインコーポレイテッド	組換えアデノウイルスおよびその使用
EA030983B1 (ru)	2013-01-07	2018-10-31	Бет Изрейэл Диконисс Медикал Сентер, Инк.	ВАКЦИНЫ, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЕ ТРИМЕРЫ ОБОЛОЧКИ (Env) ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US10248758B2 (en)	2013-02-07	2019-04-02	University Of Washington Through Its Center For Commercialization	Self-assembling protein nanostructures
EP3052132B1 (en)	2013-09-30	2020-07-29	Beth Israel Deaconess Medical Center, Inc.	Antibody therapies for human immunodeficiency virus (hiv)
WO2016037154A1 (en)	2014-09-04	2016-03-10	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Recombinant hiv-1 envelope proteins and their use
CN112121160A (zh)	2014-09-26	2020-12-25	贝斯以色列护理医疗中心有限公司	诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
US9630994B2 (en)	2014-11-03	2017-04-25	University Of Washington	Polypeptides for use in self-assembling protein nanostructures
JP6887955B2 (ja)	2015-03-18	2021-06-16	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	組換え体発現系のアッセイ
EP3390430B1 (en)	2015-12-15	2019-08-28	Janssen Vaccines & Prevention B.V.	Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
CN109219448B (zh)	2016-06-16	2022-09-20	扬森疫苗与预防公司	Hiv疫苗配制品
US10307477B2 (en)	2016-09-02	2019-06-04	Janssen Vaccines & Prevention B.V.	Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US10793607B2 (en)	2016-09-15	2020-10-06	Janssen Vaccines & Prevention B.V.	Trimer stabilizing HIV envelope protein mutations
AU2018304502B2 (en) *	2017-07-19	2022-03-31	Janssen Vaccines & Prevention B.V.	Trimer stabilizing HIV envelope protein mutations

2017
- 2017-09-14 US US15/704,651 patent/US10793607B2/en active Active
- 2017-09-14 ES ES17769027T patent/ES2824525T3/es active Active
- 2017-09-14 HU HUE17769027A patent/HUE052008T2/hu unknown
- 2017-09-14 JP JP2019514316A patent/JP7178344B2/ja active Active
- 2017-09-14 EA EA201990715A patent/EA201990715A1/ru unknown
- 2017-09-14 LT LTEP17769027.8T patent/LT3512543T/lt unknown
- 2017-09-14 WO PCT/EP2017/073141 patent/WO2018050747A1/en active Search and Examination
- 2017-09-14 MX MX2019002938A patent/MX2019002938A/es unknown
- 2017-09-14 PT PT177690278T patent/PT3512543T/pt unknown
- 2017-09-14 CA CA3036959A patent/CA3036959A1/en active Pending
- 2017-09-14 MD MDE20190798T patent/MD3512543T2/ro unknown
- 2017-09-14 MY MYPI2019001242A patent/MY190534A/en unknown
- 2017-09-14 AR ARP170102536A patent/AR109528A1/es unknown
- 2017-09-14 EP EP17769027.8A patent/EP3512543B1/en active Active
- 2017-09-14 SG SG10202001956UA patent/SG10202001956UA/en unknown
- 2017-09-14 PL PL17769027T patent/PL3512543T3/pl unknown
- 2017-09-14 KR KR1020197007592A patent/KR102513146B1/ko active IP Right Grant
- 2017-09-14 MA MA46230A patent/MA46230B1/fr unknown
- 2017-09-14 SG SG11201901206SA patent/SG11201901206SA/en unknown
- 2017-09-14 BR BR112019004593A patent/BR112019004593A2/pt unknown
- 2017-09-14 AU AU2017327672A patent/AU2017327672B2/en active Active
- 2017-09-14 DK DK17769027.8T patent/DK3512543T3/da active
- 2017-09-14 IL IL265186A patent/IL265186B/en unknown
- 2017-09-14 RS RS20201208A patent/RS60919B1/sr unknown
- 2017-09-14 EP EP20179463.3A patent/EP3747463A1/en active Pending
- 2017-09-14 IL IL294832A patent/IL294832A/en unknown
- 2017-09-14 SI SI201730416T patent/SI3512543T1/sl unknown
- 2017-09-14 CN CN201780054555.6A patent/CN109689091A/zh active Pending
- 2017-09-15 TW TW106131855A patent/TWI742158B/zh active
2019
- 2019-02-08 PH PH12019500280A patent/PH12019500280A1/en unknown
- 2019-03-14 ZA ZA2019/01597A patent/ZA201901597B/en unknown
2020
- 2020-08-13 US US16/947,694 patent/US11365222B2/en active Active
- 2020-09-14 HR HRP20201458TT patent/HRP20201458T1/hr unknown
- 2020-10-09 CY CY20201100952T patent/CY1124518T1/el unknown
- 2020-11-13 AU AU2020267278A patent/AU2020267278B2/en not_active Expired - Fee Related
2022
- 2022-06-08 US US17/805,873 patent/US11820796B2/en active Active
- 2022-11-14 JP JP2022181566A patent/JP2023011941A/ja active Pending

Also Published As

Publication number	Publication date
ES2824525T3 (es)	2021-05-12
US11365222B2 (en)	2022-06-21
AU2017327672B2 (en)	2020-10-15
MD3512543T2 (ro)	2020-11-30
AU2017327672A1 (en)	2019-02-28
LT3512543T (lt)	2020-11-10
WO2018050747A1 (en)	2018-03-22
KR20190050786A (ko)	2019-05-13
BR112019004593A2 (pt)	2019-07-02
TWI742158B (zh)	2021-10-11
KR102513146B1 (ko)	2023-03-23
PT3512543T (pt)	2020-10-13
SG11201901206SA (en)	2019-04-29
PL3512543T3 (pl)	2021-01-11
AU2020267278B2 (en)	2023-07-20
RS60919B1 (sr)	2020-11-30
CN109689091A (zh)	2019-04-26
AR109528A1 (es)	2018-12-19
MY190534A (en)	2022-04-27
IL265186B (en)	2022-09-01
IL294832A (en)	2022-09-01
MX2019002938A (es)	2019-10-15
DK3512543T3 (da)	2020-10-12
CY1124518T1 (el)	2022-03-24
CA3036959A1 (en)	2018-03-22
TW201819401A (zh)	2018-06-01
HRP20201458T1 (hr)	2020-12-11
SI3512543T1 (sl)	2020-10-30
SG10202001956UA (en)	2020-04-29
PH12019500280A1 (en)	2019-10-28
EA201990715A1 (ru)	2019-08-30
IL265186A (en)	2019-05-30
NZ750773A (en)	2021-02-26
ZA201901597B (en)	2022-12-21
JP2023011941A (ja)	2023-01-24
JP7178344B2 (ja)	2022-11-25
US10793607B2 (en)	2020-10-06
EP3512543B1 (en)	2020-07-22
MA46230B1 (fr)	2020-10-28
US20200369731A1 (en)	2020-11-26
US11820796B2 (en)	2023-11-21
EP3512543A1 (en)	2019-07-24
US20180072777A1 (en)	2018-03-15
US20220315627A1 (en)	2022-10-06
JP2019534690A (ja)	2019-12-05
AU2020267278A1 (en)	2020-12-10
MA46230A (fr)	2019-07-24
EP3747463A1 (en)	2020-12-09

Publication	Publication Date	Title
ZA201901597B (en)	2022-12-21	Trimer stabilizing hiv envelope protein mutations
ZA201806968B (en)	2020-02-26	Mdm2 protein degraders
HK1253323A1 (zh)	2019-06-14	免疫原性降低的crispr-相關(cas)蛋白
GB201502305D0 (en)	2015-04-01	Protein
GB201502306D0 (en)	2015-04-01	Protein
ZA202000335B (en)	2022-07-27	Trimer stabilizing hiv envelope protein mutations
SG11201705988UA (en)	2017-08-30	Conditionally active biological proteins
PT3531824T (pt)	2022-11-02	Proteínas inseticidas
GB201515745D0 (en)	2015-10-21	Proteins
GB201511787D0 (en)	2015-08-19	Proteins
IL263431A (en)	2019-01-31	Pharmaceutical combinations
GB201608197D0 (en)	2016-06-22	Novel proteins
HK1252269A1 (zh)	2019-05-24	由不同材料製成的箱子
GB201909518D0 (en)	2019-08-14	4-N-Butylresorcinol preparations
EP3226880A4 (en)	2018-08-29	Buchu preparations
GB201513033D0 (en)	2015-09-09	Proteins
GB2558968B (en)	2021-09-29	G Proteins
GB201522610D0 (en)	2016-02-03	Protein
IS3008B (is)	2018-12-15	Stöðgandi lausnir fyrir prótín og peptíð
ZA201808521B (en)	2021-07-28	Buchu preparation
GB201706600D0 (en)	2017-06-07	Virus preparations
GB201717288D0 (en)	2017-12-06	Hiv vaccine
IL244652B (en)	2020-02-27	Low profile stackable cutlery
GB201701439D0 (en)	2017-03-15	Fallback prevent2
TWM533627U (en)	2016-12-11	Easy-to-open envelope